Health consequences associated with choice of inhaled corticosteroid particle size in the long-term management of obstructive lung disease

Primary Investigator:

David Price, Professor of Primary Care Respiratory Medicine, University of Aberdeen, UK

Research Team:Status: Planned Study, Seeking Funding

Support:

Registration:

Short Description:

A historical observational comparison of benefits and risks in patients with obstructive lung disease managed with extra-fine and fine particle inhaled corticosteroids in UK primary care.

The primary objective of the study is to compare whether patients prescribed EF ICS are associated with a slower diabetic progression than F ICS in asthma.

The secondary objective of the study is to compare the:

  • Annual rate or incidence of ICS risks and benefits in patients with OLD managed on EF vs F ICS and on EF vs F ICS/LABA;
  • Time to first event or rate of ICS risks and benefits as appropriate in patients with OLD managed on EF vs F ICS and on EF vs F ICS/LABA;
  • Relationship between ICS exposure (average daily dose or change in average daily dose) and ICS risks and benefits will also be explored.

 

Documents and Publications

Protocol

Abstracts

Presentations

Final Publications

Additional Material